Julie M Vose Selected Research

Julie M Vose Research Topics

Disease

51	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2023 - 01/2002
48	Lymphoma (Lymphomas) 11/2023 - 01/2002
38	Neoplasms (Cancer) 04/2024 - 10/2003
33	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2021 - 10/2005
27	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2023 - 03/2003
20	B-Cell Lymphoma (Lymphoma, B Cell) 01/2024 - 06/2006
16	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2018 - 11/2003
13	Hodgkin Disease (Hodgkin's Disease) 12/2021 - 02/2002
11	Hematologic Neoplasms (Hematological Malignancy) 11/2016 - 09/2003
9	Disease Progression 02/2019 - 03/2003
6	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2023 - 01/2013
5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/2013 - 09/2007
4	Cytokine Release Syndrome 01/2024 - 12/2019
4	Genetic Translocation (Chromosomal Translocation) 08/2017 - 06/2012
4	Residual Neoplasm 10/2012 - 05/2002
3	Febrile Neutropenia 01/2023 - 07/2005
3	Thrombocytopenia (Thrombopenia) 11/2016 - 12/2006
3	Burkitt Lymphoma (Burkitt's Lymphoma) 02/2015 - 06/2006
3	Multiple Myeloma 05/2013 - 01/2007
3	Pathologic Complete Response 09/2012 - 12/2006
2	T-Cell Lymphoma (Lymphoma, T Cell) 11/2021 - 02/2010
2	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2021 - 02/2010
2	Anemia 06/2012 - 07/2005
2	Graft vs Host Disease (Graft-Versus-Host Disease) 07/2011 - 12/2004
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 05/2009 - 01/2007
2	Drug-Related Side Effects and Adverse Reactions 05/2009 - 12/2006
1	Extranodal NK-T-Cell Lymphoma 03/2024
1	Nausea 12/2021

Drug/Important Bio-Agent (IBA)

27	Rituximab (Mabthera)FDA Link 01/2019 - 04/2006
12	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2017 - 04/2002
12	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2017 - 02/2002
11	Vincristine (Oncovin)FDA LinkGeneric 12/2017 - 04/2002
10	Prednisone (Sone)FDA LinkGeneric 12/2017 - 04/2002
8	Monoclonal AntibodiesIBA 01/2015 - 01/2002
7	Lenalidomide (CC 5013)FDA Link 01/2023 - 10/2008
6	axicabtagene ciloleucelIBA 01/2024 - 01/2020
5	Chimeric Antigen ReceptorsIBA 11/2023 - 12/2019
5	Cyclin D1IBA 01/2019 - 06/2012
5	Bortezomib (Velcade)FDA Link 04/2014 - 12/2010
4	ibrutinibIBA 04/2024 - 08/2015
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2024 - 05/2009
4	MicroRNAs (MicroRNA)IBA 11/2021 - 05/2011
4	Proteins (Proteins, Gene)FDA Link 11/2021 - 07/2004
4	Etoposide (VP 16)FDA LinkGeneric 02/2016 - 01/2005
4	tositumomab I-131 (Bexxar)FDA Link 05/2013 - 01/2004
3	Immunoconjugates (Immunoconjugate)IBA 11/2023 - 01/2002
3	Agammaglobulinaemia Tyrosine KinaseIBA 11/2023 - 11/2021
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2023 - 02/2004
3	Brentuximab VedotinIBA 12/2021 - 01/2018
3	Phosphotransferases (Kinase)IBA 11/2021 - 06/2015
3	Oxidoreductases (Dehydrogenase)IBA 12/2013 - 06/2012
3	Carmustine (FIVB)FDA Link 05/2013 - 01/2005
3	Cytarabine (Cytosar-U)FDA LinkGeneric 05/2013 - 01/2005
3	Melphalan (Alkeran)FDA LinkGeneric 05/2013 - 01/2005
3	AntibodiesIBA 01/2009 - 04/2003
3	VaccinesIBA 10/2006 - 01/2002
2	palbociclibIBA 03/2024 - 01/2019
2	tocilizumab (atlizumab)FDA Link 01/2024 - 01/2021
2	Bendamustine Hydrochloride FDA Link 10/2023 - 03/2011
2	NivolumabIBA 12/2021 - 01/2018
2	Anaplastic Lymphoma KinaseIBA 01/2021 - 02/2010
2	Immunoglobulins (Immunoglobulin)IBA 01/2019 - 06/2014
2	Biomarkers (Surrogate Marker)IBA 12/2015 - 12/2003
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2013 - 12/2006
2	ParaffinIBA 09/2012 - 05/2012
2	N 30IBA 05/2012 - 11/2010
2	Proteasome InhibitorsIBA 02/2011 - 02/2005
2	Protein Kinase C betaIBA 05/2007 - 10/2005
2	HLA Antigens (Human Leukocyte Antigens)IBA 02/2007 - 09/2003
2	IodineIBA 06/2005 - 01/2004
1	Gemcitabine FDA Link 03/2024
1	brexucabtagene autoleucelIBA 10/2023
1	Immunomodulating AgentsIBA 01/2023
1	Biosimilar PharmaceuticalsIBA 01/2023
1	Complement System Proteins (Complement)IBA 11/2022
1	Circulating Tumor DNAIBA 11/2022
1	carfilzomibIBA 02/2022
1	UbiquitinIBA 01/2022
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2022
1	Messenger RNA (mRNA)IBA 11/2021
1	SphingolipidsIBA 11/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 11/2021
1	vistusertibIBA 11/2021
1	acalabrutinibIBA 11/2021

Therapy/Procedure

68	Therapeutics 04/2024 - 01/2002
29	Drug Therapy (Chemotherapy) 03/2024 - 05/2002
18	Hematopoietic Stem Cell Transplantation 01/2019 - 05/2002
16	Stem Cell Transplantation 01/2023 - 12/2004
15	Transplantation 01/2023 - 04/2003
12	Cell Transplantation 12/2021 - 05/2006
8	Autologous Transplantation 11/2014 - 05/2002
7	Immunotherapy 01/2017 - 01/2004
5	Radioimmunotherapy 05/2013 - 04/2003
4	Salvage Therapy 12/2021 - 07/2011
3	Radiotherapy 03/2024 - 02/2005
3	Aftercare (After-Treatment) 05/2009 - 02/2005
2	Highly Active Antiretroviral Therapy (HAART) 02/2015 - 11/2012
2	Homologous Transplantation 11/2012 - 08/2012
2	Bone Marrow Transplantation (Transplantation, Bone Marrow) 04/2005 - 04/2003
1	Precision Medicine 11/2022